Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellectis S.A., a foreign private issuer headquartered in Paris, France, on June 9, 2026. The filing serves to distribute a press release dated June 9, 2026, to U.S. investors. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and exhibit index. It does not include the content of the press release or any financial statements. Consequently, no data is available regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. The nature of the update is limited to the existence of a press release, the content of which is not included in the source text.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, contingencies, and unusual items are not disclosed in the provided text. The document only identifies the Chief Executive Officer, André Choulika, as the authorized signatory.
Investor Verification Checklist
- Verify the full content of the press release dated June 9, 2026, referenced as Exhibit 99.1, as it is not included in this summary.
- Confirm whether the press release contains material non-public information regarding clinical trials, partnerships, or financial results.
- Review the company's most recent Form 20-F for the latest audited financial data, as this 6-K does not contain financial figures.